Physician profile
John D Ledbetter
NPI 1750355004
$6,949.81
in general payments reported to CMS, 2019-2025
34 companies · $72.57 in 2025
The $72.57 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,345 · 2020: $1,185 · 2022: $490 · 2023: $414 · 2024: $443 · 2025: $72.57.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $929.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $929.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,726.67 | 2019-2024 | |
| Novo Nordisk INC | $1,254.50 | 2019-2024 | Wegovy |
| Amgen INC. | $708.20 | 2019-2022 | |
| Lilly USA, LLC | $622.60 | 2019-2025 | Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $402.81 | 2019-2024 | Farxiga |
| Amarin Pharma, INC. | $317.35 | 2019-2020 | |
| Gilead Sciences, INC. | $313.07 | 2019-2020 | |
| Allergan, INC. | $255.23 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $156.25 | 2019-2025 | Capvaxive, Gardasil 9 |
| Bayer Healthcare Pharmaceuticals INC. | $125.80 | 2022-2024 | |
| Corcept Therapeutics | $123.41 | 2024-2025 | Korlym |
| Janssen Pharmaceuticals, INC | $120.91 | 2019-2020 | |
| Exactech, INC. | $106.59 | 2019 | |
| Astellas Pharma US INC | $103.34 | 2019 | |
| Glaxosmithkline, LLC. | $94.16 | 2019-2023 | Shingrix, Arexvy |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $68.95 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $53.16 | 2019-2020 | |
| Abbvie INC. | $51.96 | 2019-2023 | |
| Radius Health, INC. | $43.31 | 2019 | |
| Genentech USA, INC. | $41.65 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.79 | 2020-2023 | Jardiance |
| Exact Sciences Corporation | $27.52 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Phathom Pharmaceuticals, INC. | $25.22 | 2024 | Voquezna |
| Optinose US, INC. | $21.50 | 2019 | |
| Neuronetics, INC. | $21.20 | 2022 | |
| Shire North American Group INC | $20.13 | 2019 | |
| Abbott Laboratories | $19.09 | 2023 | Freestyle Libre 3 |
| Ultragenyx Pharmaceutical INC. | $17.90 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $12.48 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.35 | 2020 | |
| Nalpropion Pharmaceuticals LLC | $12.09 | 2019 | |
| Circassia INC. | $11.80 | 2019 | |
| Eisai INC. | $10.92 | 2019 | |
| Boston Scientific Corporation | $10.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ledbetter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.